These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 21083671

  • 1. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
    Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ.
    Aliment Pharmacol Ther; 2011 Jan; 33(2):185-93. PubMed ID: 21083671
    [Abstract] [Full Text] [Related]

  • 2. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
    Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S.
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1276-85. PubMed ID: 20298497
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Certolizumab pegol for the treatment of Crohn's disease.
    Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, PRECISE 1 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):228-38. PubMed ID: 17634458
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
    Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A, CDP870 Crohn's Disease Study Group.
    Gastroenterology; 2005 Sep 19; 129(3):807-18. PubMed ID: 16143120
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS, Nelson M, Dolder CR.
    Ann Pharmacother; 2010 Feb 19; 44(2):333-42. PubMed ID: 20118143
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.
    Feagan BG, Hanauer SB, Coteur G, Schreiber S.
    Aliment Pharmacol Ther; 2011 May 19; 33(10):1143-51. PubMed ID: 21443536
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
    Shao LM, Chen MY, Cai JT.
    Aliment Pharmacol Ther; 2009 Mar 15; 29(6):605-14. PubMed ID: 19183161
    [Abstract] [Full Text] [Related]

  • 19. Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease.
    Baker DE.
    Rev Gastroenterol Disord; 2008 Mar 15; 8(4):240-53. PubMed ID: 19107098
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.